Physician profile

Alex G Hirsch

Obstetrics & Gynecology · Hewlett, NY

NPI 1902895121

$891.30

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$70.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Celularity INC. $300.00 2022
Abbvie INC. $202.93 2019-2021
Therapeuticsmd, INC. $167.83 2019-2022
Exeltis, USA INC. $60.15 2020-2021
Pfizer INC. $32.66 2021-2023
Millicent US INC $32.31 2020-2023 Femring, Intrarosa
Coopersurgical, INC. $31.90 2023 Paragard T 380a
Medtronic, INC. $25.00 2021
Myovant Sciences INC. $20.52 2021
Vertical Pharmaceuticals, LLC $18.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alex G Hirsch

$891.30

in general payments reported 2019-2025

Years
2019-2023
Top company
Celularity INC.

https://glasscript.com/doctor/313676/alex-g-hirsch

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.